In rodent models of angiotensin II-induced or SLE-associated hypertension, treatment with bortezomib at a range of doses (50, 200, 750 μg/kg) was effective at lowering mean arterial pressure (8, 47, 48). This evidence concerns the gene AGT and hypertensive disorder.